Immunovant shares the full details from its earnings call for the first quarter of 2027.

Oct 14, 2026, 5:05 AM ETResultsRead the original at Benzinga

Good for IMVT

Immunovant expects to launch brepocitinib by September's end, has begun a new phase 3 study, and received another Moderna payment. FDA action and study results remain pending, and the company still pursues Pfizer and BioNTech; nearly $4 billion in cash compares with reported research and office costs.

IMVT · Immunovant

AI read · Good for IMVT

The AI's read

If the FDA clears brepocitinib, Immunovant could begin selling the medicine and build its presence across several illnesses. The new study adds another chance to show the medicine helps patients, but its results are still ahead. The company also reported large research and office costs, alongside nearly $4 billion in cash. It has received a Moderna payment and is still pursuing Pfizer and BioNTech, so further legal payments are not certain.

Get alerts for IMVT

Follow Immunovant (IMVT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IMVT

Free on the App Store and Google Play, or on the web.